New IPMG Board Strengthens Commitment to Availability of Innovative Medicines
Jakarta, VIVA – The International Pharmaceutical Manufacturers Group (IPMG), an association representing 25 multinational research-based pharmaceutical companies in Indonesia, has announced the composition of its Board of Directors for the 2026–2028 period.
IPMG member companies have once again entrusted leadership to Evie Yulin (President Director of Merck Indonesia) as Chair and George Stylianou (President Director of Merck Sharp and Dohme Indonesia) as Vice Chair of IPMG.
Members believe that their leadership will continue to deliver meaningful impact for patients in Indonesia, the healthcare system, and the industry in advancing IPMG’s vision and mission.
“I feel honoured and enthusiastic to continue IPMG’s advocacy efforts in improving the availability and access to innovative medicines in Indonesia. Currently, only around 9 percent of innovative medicines are available in Indonesia, and only about 2 percent can be accessed through public funding. Bridging this gap remains IPMG’s top priority, and through strong collaboration, we are committed to ensuring that more patients can benefit from innovative medicines, strengthening public health, and supporting the achievement of the Golden Indonesia 2045 vision,” said IPMG Chair Evie Yulin, quoted on Tuesday, 7 April 2026.
This newly approved Board of Directors brings leaders with diverse expertise, including in Health Technology Assessment (HTA), pricing and procurement mechanisms, regulatory frameworks, ethics, medical and patient safety, as well as health investment.
This reflects a coordinated approach to strengthening Indonesia’s health ecosystem.
IPMG remains committed to improving the availability and access to innovative medicines for patients in Indonesia. Although progress has been made, access remains limited, underscoring the importance of ongoing collaboration.
IPMG continues to advocate for a predictable and transparent policy environment, strengthening the implementation of Health Technology Assessment (HTA) including through stakeholder-led submissions (SLS) mechanisms, developing sustainable pricing and procurement mechanisms, and stronger alignment between registration pathways, financing, and patient access.
“IPMG will continue to play a constructive role in supporting policy dialogue and strengthening implementation aligned with national health priorities. We remain open to collaboration to build a more resilient health system and enhance Indonesia’s competitiveness,” added IPMG Executive Director Ani Rahardjo.